-
TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020
TR1 – Notification of major interest in shares by Lanstead Capital – 3 April 2020 To view document click here
-
TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020
TR1 – Notification of major interest in shares from Robert Zimmer – 2 April 2020 To view document click here
-
Subscription to raise £1.5 million to fund expansion of R&D pipeline
ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), the specialist drug discovery and development company, is pleased to announce subscriptions to raise £1.5 million (the “Subscriptions”) through the issue of 15,000,000 new ordinary share of 10 pence each in the Company (“Ordinary Shares”) (the “Subscription Shares”) at a price of 10p per Ordinary Share…
-
Incanthera plc – Admission to trading on the NEX Exchange Growth Market Publication of Admission Document
ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that further to its announcement on 17 February 2020, Incanthera plc (“Incanthera”), a specialist oncology company, has today been admitted to the NEX Exchange Growth Market (TIDM: INC) and has published its Admission Document. Following Admission to trading,…
-
Oncology specialist Incanthera, in which ImmuPharma currently has a 14.0% shareholding, announces Rule 23 Notice in advance to quoting on NEX Exchange Growth Market
ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, notes that the NEX Exchange Growth Market (“NEX”) has today released a pre-admission announcement under Rule 23 of the intention of Incanthera plc (“Incanthera”), a specialist oncology company, to quote on NEX. ImmuPharma currently holds a 14.0% shareholding in…
-
ImmuPharma provides an update on the Avion Agreement in relation to Lupuzor’s™ new international Phase III trial
ImmuPharma PLC (LSE AIM: IMM – Euronext Growth: ALIMM), a specialist drug discovery and development company, announces an update on activities with Avion Pharmaceuticals LLC (“Avion”) following the successful licence and development agreement signed with Avion in November 2019 for the exclusive rights to Lupuzor™ in North America (United States). A summary of key activities…
-
Admission to trading on Euronext Growth Brussels
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), a specialist drug discovery and development company, is pleased to announce that, this morning at approximately 09.00am (GMT), ImmuPharma will commence trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’. This new listing does not affect the trading of ImmuPharma’s shares on AIM, nor is there any intention…
-
Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, is pleased to announce that, further to the announcement of 13 December 2019, that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’, it has today published the Information Note, as required by the Euronext Growth Market Rules Book…
-
Dual listing on Euronext growth Brussels
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company is pleased to announce that its shares will be admitted to trading on Euronext Growth Brussels (“Euronext”) under ticker ‘ALIMM’ following the approval by Euronext of its request for listing. Admission is expected to take effect from 19 December 2019. This new listing does not…
-
Share price volatility
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company’s share price and speculation concerning a…
